COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
A trial with a trivalent influenza subunit vaccine prepared with sodium deoxycholate was carried out in 88 volunteers between May and November 1981. Each haemagglutinin antigen was present at 7 micrograms per dose. Fourfold or greater haemagglutination inhibition antibody (HI) responses to the H1N1 virus A/Brazil/11/78 occurred in 70% of volunteers following a single dose. For the H3N2 virus A/Bangkok/1/79 and B/Singapore/222/79 these figures were 52 and 11%, respectively. No increase in the antibody titre was noted to any of the antigens following a second vaccination dose. Antibody levels remained relatively constant six months after vaccination. A response to B/Singapore/222/79, comparable with the HI response for the influenza A antigens, was noted when serum titres were estimated by a plaque reduction procedure. No neuraminidase inhibition antibody could be detected in response to either A/Brazil/11/78 or A/Bangkok/1/79. No reactions specifically attributable to the vaccine occurred after either injection. A lower HI response to A/Brazil/11/78 was noted in volunteers 52 years of age and older, who also showed less evidence of earlier priming to this virus. Levels of nasal wash neutralizing antibodies to A/Brazil/11/78 were proportional to those detected in sera by HI tests, but were present in smaller amounts.